Upadacitinib for the Treatment of Moderate-to-Severe Crohn’s Disease

References

• Torres J , MehandruS, ColombelJF, Peyrin-BirouletL. Crohn’s disease. Lancet389(10080), 1741–1755 (2017).
   PubMed Web of Science ®Google Scholar
• Tsai L , MaC, DulaiPSet al. Contemporary risk of surgery in patients with ulcerative colitis and crohn’s disease: a meta-analysis of population-based cohorts. Clin. Gastroenterol. Hepatol.19(10), 2031–2045 e2011 (2021).
   PubMed Web of Science ®Google Scholar
• Turner D , RicciutoA, LewisAet al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology160(5), 1570–1583 (2021).
   PubMed Web of Science ®Google Scholar
• Le Berre C , RicciutoA, Peyrin-BirouletL, TurnerD. Evolving short- and long-term goals of management of inflammatory bowel diseases: getting it right, making it last. Gastroenterology162(5), 1424–1438 (2022).
   PubMed Web of Science ®Google Scholar
• Geyl S , GuilloL, LaurentV, D’amicoF, DaneseS, Peyrin-BirouletL. Transmural healing as a therapeutic goal in Crohn’s disease: a systematic review. Lancet Gastroenterol. Hepatol.6(8), 659–667 (2021).
   PubMed Web of Science ®Google Scholar
• Targan SR , HanauerSB, Van DeventerSJet al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N. Engl. J. Med.337(15), 1029–1035 (1997).
   PubMed Web of Science ®Google Scholar
• Hanauer SB , FeaganBG, LichtensteinGRet al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet359(9317), 1541–1549 (2002).
   PubMed Web of Science ®Google Scholar
• Hanauer SB , SandbornWJ, RutgeertsPet al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology130(2), 323–333 (2006).
   PubMed Web of Science ®Google Scholar
• Hanauer S , LukášM, MacintoshD, RutgeertsP, SandbornW, PollackP. A randomized, double-blind, placebo-controlled trial of the human anti-TNF-a monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn’s disease. Gastroenterology127, 332 (2004).
   Web of Science ®Google Scholar
• Sandborn WJ , FeaganBG, RutgeertsPet al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N. Engl. J. Med.369(8), 711–721 (2013).
   PubMed Web of Science ®Google Scholar
• Feagan BG , SandbornWJ, GasinkCet al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N. Engl. J. Med.375(20), 1946–1960 (2016).
   PubMed Web of Science ®Google Scholar
• D’Haens G , PanaccioneR, BaertFet al. Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet399(10340), 2015–2030 (2022).
   PubMed Web of Science ®Google Scholar
• Ferrante M , PanaccioneR, BaertFet al. Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet399(10340), 2031–2046 (2022).
   PubMed Web of Science ®Google Scholar
• Loftus EV Jr , PanesJ, LacerdaAPet al. Upadacitinib induction and maintenance therapy for Crohn’s disease. N. Engl. J. Med.388(21), 1966–1980 (2023).
   PubMed Web of Science ®Google Scholar
• Roda G , JharapB, NeerajN, ColombelJ-F. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin. Transl. Gastroenterol.7(1), e135 (2016).
   PubMed Web of Science ®Google Scholar
• Singh J , WellsG, ChristensenRet al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst. Rev.2, CD008794 (2011).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ , PanesJ, SandsBEet al. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Aliment. Pharmacol. Ther.50(10), 1068–1076 (2019).
   PubMed Web of Science ®Google Scholar
• Ytterberg SR , BhattDL, MikulsTRet al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N. Engl. J. Med.386(4), 316–326 (2022).
   PubMed Web of Science ®Google Scholar
• Schreiber S , Ben-HorinS, LeszczyszynJet al. Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease. Gastroenterology160(7), 2340–2353 (2021).
   PubMed Web of Science ®Google Scholar
• Vermeire S , D’HaensG, BaertFet al. Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn’s disease: results from the VISIBLE 2 randomised trial. J. Crohn’s Colitis16(1), 27–38 (2022).
   Google Scholar
• Bots SJ , ParkerCE, BrandseJFet al. Anti-drug antibody formation against biologic agents in inflammatory bowel disease: a systematic review and meta-analysis. BioDrugs35(6), 715–733 (2021).
   PubMed Web of Science ®Google Scholar
• Pouillon L , TravisS, BossuytP, DaneseS, Peyrin-BirouletL. Head-to-head trials in inflammatory bowel disease: past, present and future. Nat. Rev. Gastroenterol. Hepatol.17(6), 365–376 (2020).
   PubMed Web of Science ®Google Scholar
• Sands BE , IrvingPM, HoopsTet al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet399(10342), 2200–2211 (2022).
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L , ChapmanJC, ColombelJ-Fet al. LB01 Risankizumab versus ustekinumab for patients with moderate to severe Crohn’s disease: results from the phase 3B sequence study. United Eur. Gastroenterol. J.11(S8), 150–151 (2023).
   Google Scholar
• Barberio B , GracieDJ, BlackCJ, FordAC. Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn’s disease: systematic review and network meta-analysis. Gut72(2), 264–274 (2023).
   PubMed Web of Science ®Google Scholar
• Vuyyuru SK , ShackeltonLM, HanzelJ, MaC, JairathV, FeaganBG. Targeting IL-23 for IBD: rationale and progress to date. Drugs83(10), 873–891 (2023).
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration . FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions (2021). www.fda.gov/drugs/fda-drug-safety-podcasts/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death#:∼:text=On%20September%201%2C%202021%2C%20based,medicines%20Xeljanz%20and%20Xeljanz%20XR
   Google Scholar
• Sandborn WJ , D’HaensGR, SandsBEet al. Tofacitinib for the treatment of ulcerative colitis: an integrated summary of up to 7.8 years of safety data from the Global Clinical Programme. J Crohn’s Colitis17(3), 338–351 (2023).
   Google Scholar
• Danese S , ArgolloM, LeBerre C, Peyrin-BirouletL. JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?Gut68(10), 1893–1899 (2019).
   PubMed Web of Science ®Google Scholar
• Salas A , Hernandez-RochaC, DuijvesteinMet al. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol.17(6), 323–337 (2020).
   PubMed Web of Science ®Google Scholar
• De Vries LCS , WildenbergME, DeJonge WJ, D’HaensGR. The future of Janus kinase inhibitors in inflammatory bowel disease. J. Crohn’s Colitis11(7), 885–893 (2017).
   Google Scholar
• Schreiber S , RosenstielP, HampeJet al. Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut51(3), 379–385 (2002).
   PubMed Web of Science ®Google Scholar
• Wu F , DassopoulosT, CopeLet al. Genome-wide gene expression differences in Crohn’s disease and ulcerative colitis from endoscopic pinch biopsies: insights into distinctive pathogenesis. Inflamm. Bowel Dis.13(7), 807–821 (2007).
   PubMed Web of Science ®Google Scholar
• Arijs I , LiK, ToedterGet al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut58(12), 1612–1619 (2009).
   PubMed Web of Science ®Google Scholar
• Choy EH . Clinical significance of Janus kinase inhibitor selectivity. Rheumatology58(6), 953–962 (2019).
   PubMed Web of Science ®Google Scholar
• Jordan AA , HigginsPD. The role of upadacitinib in the treatment of ulcerative colitis. Immunotherapy15(10), 713–727 (2023).
   PubMed Web of Science ®Google Scholar
• Sanmarti R , CorominasH. Upadacitinib for patients with rheumatoid arthritis: a comprehensive review. J. Clin. Med.12(5), 1734 (2023).
   PubMed Web of Science ®Google Scholar
• Ross Y , MagreyM. Use of upadacitinib in the treatment of psoriatic arthritis. Immunotherapy13(18), 1549–1554 (2021).
   PubMed Web of Science ®Google Scholar
• George N , LiewJW, DubreuilM. The role of upadacitinib for the treatment of axial spondyloarthritis. Immunotherapy15(15), 1227–1237 (2023).
   PubMed Web of Science ®Google Scholar
• Navarro-Triviño F , Alcantara-LunaS, Domínguez-CruzJet al. Upadacitinib for moderate to severe atopic dermatitis. Immunotherapy15(11), 799–808 (2023).
   PubMed Web of Science ®Google Scholar
• Parmentier JM , VossJ, GraffCet al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol.2, 23 (2018).
   PubMedGoogle Scholar
• Mohamed MF , KlunderB, OthmanAA. Clinical pharmacokinetics of upadacitinib: review of data relevant to the rheumatoid arthritis indication. Clin. Pharmacokinet.59(5), 531–544 (2020).
   PubMed Web of Science ®Google Scholar
• Trueman S , MohamedMF, FengT, LacerdaAP, MarburyT, OthmanAA. Characterization of the effect of hepatic impairment on upadacitinib pharmacokinetics. J. Clin. Pharmacol.59(9), 1188–1194 (2019).
   PubMed Web of Science ®Google Scholar
• Mohamed MF , TruemanS, FengT, AndersonJ, MarburyTC, OthmanAA. Characterization of the effect of renal impairment on upadacitinib pharmacokinetics. J. Clin. Pharmacol.59(6), 856–862 (2019).
   PubMed Web of Science ®Google Scholar
• Mohamed MF , JungerwirthS, AsatryanA, JiangP, OthmanAA. Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib. Br. J. Clin. Pharmacol.83(10), 2242–2248 (2017).
   PubMed Web of Science ®Google Scholar
• Mohamed MF , KlunderB, LacerdaAP, OthmanAA. Exposure-response analyses for upadacitinib efficacy and safety in the Crohn’s disease CELEST study and bridging to the extended-release formulation. Clin. Pharmacol. Ther.107(3), 639–649 (2020).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ , FeaganBG, LoftusEVJret al. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn’s disease. Gastroenterology158(8), 2123–2138 (2020).
   PubMed Web of Science ®Google Scholar
• Daperno M , D’HaensG, Van AsscheGet al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest. Endosc.60(4), 505–512 (2004).
   PubMed Web of Science ®Google Scholar
• Bretz F , PinheiroJC, BransonM. Combining multiple comparisons and modeling techniques in dose-response studies. Biometrics61(3), 738–748 (2005).
   PubMed Web of Science ®Google Scholar
• Panaccione R , LindsayJO, PanesJet al. OP147 upadacitinib 30 mg treatment restores clinical response after loss of response in patients with moderately to severely active crohn’s disease: results from the phase 3 u-endure study. United Eur. Gastroenterol. J.11(S8), 138–139 (2023).
   PubMedGoogle Scholar
• Peyrin-Biroulet L , ParkesG, RodríguezCet al. OP16 Endoscopic and clinical outcomes of upadacitinib in patients with moderately to severely active Crohn’s disease by number and type of prior biologics. J. Crohn’s Colitis17(Suppl. 1), i20–i22 (2023).
   Google Scholar
• Colombel JF , IrvingP, RiederFet al. P491 Efficacy and safety of upadacitinib for the treatment of fistulas and fissures in patients with Crohn’s disease. J. Crohn’s Colitis17(Suppl. 1), i620–i623 (2023).
   Google Scholar
• Nunez P , QueraR, YarurAJ. Safety of Janus kinase inhibitors in inflammatory bowel diseases. Drugs83(4), 299–314 (2023).
   PubMed Web of Science ®Google Scholar
• Olivera PA , LasaJS, BonovasS, DaneseS, Peyrin-BirouletL. Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology158(6), 1554–1573 e1512 (2020).
   PubMed Web of Science ®Google Scholar
• Din S , SelingerCP, BlackCJ, FordAC. Systematic review with network meta-analysis: risk of herpes zoster with biological therapies and small molecules in inflammatory bowel disease. Aliment. Pharmacol. Ther. doi: 10.1111/apt.17379 (2022).
   PubMed Web of Science ®Google Scholar
• Fleischmann R , CurtisJR, Charles-SchoemanCet al. Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme. Ann. Rheum. Dis.82(9), 1130–1141 (2023).
   PubMed Web of Science ®Google Scholar
• US FDA . Rinvoq (upadacitinib) (2023). www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/211675Orig1s015ltr.pdf
   Google Scholar
• European Medicines Agency . Summary of CHMP opinion for Rinvoq (upadacitinib) (2023). www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-rinvoq-ii-27_en.pdf.
   Google Scholar
• European Medicines Agency . Rinvoq: EPAR – Scientific conclusions and grounds for the variation to the terms of the marketing authorisation (2023). www.ema.europa.eu/en/documents/scientific-conclusion/rinvoq-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf
   Google Scholar